Laboratorios Farmaceuticos Rovi, S.A. (LABFF) Stock Analysis

Laboratorios Farmaceuticos Rovi, S.A. (LABFF) Healthcare & Pipeline Overview

Laboratorios Farmaceuticos Rovi, S.A. is a Spanish biopharmaceutical company specializing in the development, manufacturing, and marketing of proprietary and licensed pharmaceutical products, including low-molecular-weight heparins and contrast agents, while also providing contract manufacturing services, positioning it as a diversified player in the global healthcare market.

What Is the Investment Thesis for LABFF?

The company's focus on specialized medications, such as low-molecular-weight heparins and contrast agents, provides a stable revenue base. The collaboration with Moderna for mRNA COVID-19 vaccine manufacturing represents a significant growth catalyst. With a market capitalization of $3.44B and a P/E ratio of 22.29, Rovi's valuation reflects its growth potential. Key risks include competition from generic drug manufacturers and potential regulatory changes in the pharmaceutical industry. The company's strong gross margin of 63.8% and a profit margin of 18.9% indicate efficient operations and profitability.

Based on FMP financials and quantitative analysis

LABFF Key Highlights

Market capitalization of $3.44B reflects investor confidence in Rovi's growth prospects.

• P/E ratio of 22.29 indicates a premium valuation, suggesting expectations of future earnings growth.
• Gross margin of 63.8% demonstrates strong pricing power and efficient cost management.
• Profit margin of 18.9% highlights Rovi's ability to generate profits from its revenue streams.
• Dividend yield of 1.17% provides a modest income stream for investors.

Who Are LABFF's Competitors?

LABFF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are LABFF's Key Strengths?

Diversified product portfolio

• Strong contract manufacturing capabilities
• Established presence in Europe
• Collaboration with Moderna

What Are LABFF's Weaknesses?

Reliance on a limited number of key products

• Exposure to generic competition
• Limited geographic diversification
• Dependence on contract manufacturing agreements

What Could Drive LABFF Stock Higher?

Continued demand for Rovi's proprietary pharmaceutical products, including low-molecular-weight heparins and contrast agents.

• Expansion of contract manufacturing services with existing and new pharmaceutical partners.
• Revenue generation from the collaboration with Moderna for manufacturing mRNA COVID-19 vaccine candidate.
• Potential regulatory approvals for new pharmaceutical products in development.
• Expansion into new geographic markets, particularly in emerging economies.

What Are the Key Risks for LABFF?

Competition from generic drug manufacturers eroding market share for key products.

• Regulatory changes in the pharmaceutical industry impacting pricing and market access.
• Economic downturns reducing healthcare spending and demand for pharmaceutical products.
• Patent expirations leading to decreased revenue from proprietary drugs.
• Dependence on contract manufacturing agreements, which can be terminated or renegotiated.

What Are the Growth Opportunities for LABFF?

• Expansion of Contract Manufacturing Services: Rovi's contract manufacturing business represents a significant growth opportunity. The global pharmaceutical contract manufacturing market is projected to reach $228.17 billion by 2028, growing at a CAGR of 6.7%. By leveraging its manufacturing capabilities and expertise, Rovi can secure additional contracts from pharmaceutical companies seeking to outsource production.
• Increased Demand for Biosimilars: The rising demand for biosimilars, driven by cost containment pressures and patent expirations of blockbuster drugs, presents a growth opportunity for Rovi. The global biosimilars market is projected to reach $107.63 billion by 2029, growing at a CAGR of 20.7%. Rovi's Enoxaparin biosimilar Becat positions it to capitalize on this trend.
• Geographic Expansion: Rovi has the opportunity to expand its geographic presence beyond its current markets in Spain, the European Union, and OECD countries. Entering new markets, particularly in emerging economies with growing healthcare expenditures, can drive revenue growth. This expansion could involve direct sales, partnerships, or acquisitions.
• Development of Novel Pharmaceutical Products: Investing in research and development to create novel pharmaceutical products can drive long-term growth for Rovi. Focusing on therapeutic areas with unmet medical needs, such as cardiovascular disease, oncology, and neurology, can lead to the development of innovative drugs with high market potential. This strategy requires significant investment and carries inherent risks.
• Collaboration with Moderna: The collaboration with Moderna for manufacturing mRNA COVID-19 vaccine candidate represents a significant growth opportunity for Rovi. As the demand for COVID-19 vaccines continues, Rovi can generate substantial revenue from its manufacturing agreement. Furthermore, this collaboration could lead to additional partnerships with Moderna or other biotechnology companies in the future.

What Are LABFF's Competitive Advantages?

• Specialized Product Portfolio: Rovi's focus on specialized medications, such as low-molecular-weight heparins and contrast agents, creates a niche market position.
• Contract Manufacturing Expertise: Rovi's expertise in contract manufacturing provides a competitive advantage.
• Established Relationships: Rovi has established relationships with wholesalers, doctors, nursing staff, pharmacists, and patients.
• Collaboration with Moderna: The collaboration with Moderna provides access to innovative mRNA technology and manufacturing opportunities.

What Does LABFF Do?

Laboratorios Farmaceuticos Rovi, S.A., founded in 1946 and headquartered in Madrid, Spain, is a pharmaceutical company engaged in the research, development, production, and commercialization of pharmaceutical products. The company operates in Spain, the European Union, OECD countries, and internationally. Rovi's core business revolves around both proprietary pharmaceutical products and contract manufacturing services for other pharmaceutical companies. Its product portfolio includes Hibor and Enoxaparin biosimilar Becat, low-molecular-weight heparins used to prevent and treat venous thromboembolic disease. Other key products include Neparvis for chronic heart failure, Absorcol for hypercholesterolemia, bronchodilators Hirobriz Breezhaler and Ulunar Breezhaler for chronic obstructive pulmonary disease, and Volutsa for benign prostatic hyperplasia. Additionally, Rovi markets hospital products for imaging diagnosis, such as Iomeron and Iopamiro for computed tomography, Multihance and Prohance for magnetic resonance imaging, and Sonovue for ultrasounds. The company also offers contract manufacturing services, producing prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets for other pharmaceutical companies. Rovi serves a diverse customer base, including wholesalers, doctors, nursing staff, pharmacists, and patients. The company has a collaboration with Moderna, Inc. for manufacturing mRNA COVID-19 vaccine candidate.

What Products and Services Does LABFF Offer?

• Researches and develops pharmaceutical products.
• Produces and sells pharmaceutical products in Spain, the EU, OECD countries, and internationally.
• Distributes products licensed from other laboratories.
• Manufactures low-molecular-weight heparins to prevent and treat venous thromboembolic disease.
• Markets products for the treatment of chronic heart failure and hypercholesterolemia.
• Offers products for the treatment of chronic obstructive pulmonary diseases and benign prostatic hyperplasia.
• Provides hospital products for imaging diagnosis.
• Offers contract-manufacturing services to other pharmaceutical companies.

How Does LABFF Make Money?

• Develops and manufactures proprietary pharmaceutical products.
• Generates revenue through the sale of its own branded products.
• Provides contract manufacturing services to other pharmaceutical companies.
• Collects fees for manufacturing pharmaceutical products on behalf of other companies.

What Industry Does LABFF Operate In?

Laboratorios Farmaceuticos Rovi, S.A. operates within the biotechnology industry, a sector characterized by rapid innovation, intense competition, and stringent regulatory oversight. The global biotechnology market is projected to reach $3.44 trillion by 2030, growing at a CAGR of 12.3% from 2022. Rovi competes with other pharmaceutical companies, including AKBLF (Akebia Therapeutics Inc), CAMRF (Camber Energy Inc), CSMYF (CMS Energy Corp), CZMWF (CZ BioTech), and GNNSF (Genus PLC). Rovi's focus on specialized medications and contract manufacturing services differentiates it from competitors.

Who Are LABFF's Key Customers?

• Wholesalers
• Nursing staff
• Pharmacists

Laboratorios Farmaceuticos Rovi, S.A.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 6.79 places it in the safe zone, indicating low near-term bankruptcy risk.

Quarterly Financial Performance: Laboratorios Farmaceuticos Rovi, S.A.

Revenue for Laboratorios Farmaceuticos Rovi, S.A. came in at $222.4M during Q2 FY2026, a 25.2% improvement versus the preceding quarter. The company recorded net income of $87.0M, with diluted EPS of $1.71. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, LABFF averaged $1.05 in diluted EPS.

LABFF Valuation & Market Position

With a $3.44B market cap, Laboratorios Farmaceuticos Rovi, S.A. sits in the mid-cap segment of the market.

Return on equity for Laboratorios Farmaceuticos Rovi, S.A. stands at 20.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 14.2%, showing how much profit it generates from its asset base. LABFF trades at a trailing price-to-earnings ratio of 22.29, roughly in line with the Healthcare sector average of ~21.50x. Its free cash flow yield is 3.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.66 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.5%, the inverse of the P/E and a quick read on earnings relative to price.

Company Profile

Laboratorios Farmaceuticos Rovi, S.A. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Pozuelo de Alarcón, ES. The company is led by CEO Juan Lopez-Belmonte Encina. LABFF has traded publicly since 2021.

LABFF Financials

LABFF Latest News

LABFF Analyst Consensus

LABFF MoonshotScore

What Investors Ask About Laboratorios Farmaceuticos Rovi, S.A. (LABFF) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources